Pfizer Lyme Disease Vaccine Shows 70% Effectiveness in Phase 3 Trial

Pfizer and Valneva report that their Lyme disease vaccine achieved approximately 70% effectiveness in a phase 3 trial, marking a potential first human vaccine for the disease if approved.

Lyme disease, transmitted by blacklegged ticks, can lead to severe arthritis, neurological, and cardiac complications. While initial analyses did not meet pre-specified statistical criteria due to fewer-than-expected cases, a second analysis did, prompting the companies to prepare regulatory submissions.

Public health experts highlight the potential to reduce Lyme-related morbidity and provide preventive options for populations at risk during outdoor activities. Read more from The Hill here.